Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
URC102 in Gout Patients
NCT02557126Phase 2Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Oct 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of epaminurad in gout, hyperuricemia, sponsored by JW Pharmaceutical Corporation. Started Oct 2015; status: completed.
02
Drugs
epaminurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT02557126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02557126.